Myeloid growth factors: Clinical practice guidelines in oncology™

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 2, 2007, Pages 188-202

  Crawford, Jeffrey ^a   Althaus, Betsy ^a   Armitage, James ^a   Balducci, Lodovico ^a   Bennett, Charles ^a   Blayney, Douglas W ^a   Cataland, Spero R ^a   Dale, David C ^a   Demetri, George D ^a   Erba, Harry P ^a   Foran, James ^a   Freifeld, Alison G ^a   Heaney, Mark L ^a   Htoy, Sally ^a   Kloth, Dwight D ^a   Lyman, Gary H ^a   Messersmith, Wells A ^a   Michaud, Laura Boehnke ^a   Miyata, Sarah C ^a   Robbins, Amy ^a   Tallman, Martin S ^a   Vadhan Raj, Saroj ^a   Westervelt, Peter ^a   Wong, Michael K ^a   more..

^a NONE

Author keywords

Chemotherapy; Fever; Myeloid growth factors; NCCN Clinical Practice Guidelines; Neutropenia

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYELOID GROWTH FACTOR; NAVELBINE; OXALIPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; FEBRILE BONE MARROW APLASIA; FEBRILE NEUTROPENIA; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 33947213304     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0019     Document Type: Conference Paper

References (25)

1. Dale DC, McCarter GC, Crawford J, et al. Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review. J Natl Compr Canc Netw 2003; 1:440-454.
2. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(suppl 1):1-15.
3. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002;62(suppl 1):65-78.
4. Smith TJ, Khatcheressian J, Lyman OH et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187-3205.
5. Kuderer NM, Crawford H, Dale DC, Lyman GH. Meta-analysis of prophylactic granulocyte colony-stimulating factor (GCSF) in cancer patients receiving chemotherapy [abstract]. J Clin Oncol 2005;23(suppl 1):788. Abstract 8117.
6. Lyman OH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of FN. Crit Rev Oncol Hematol 2004;50:129-146.
7. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406-411.
8. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte stimulating factor to reduce the incidence of chemotherapy-induced FN in adult patients with lymphomas and solid tumors. Eur J Cancer 2006;42:2433-2453.
9. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents FN in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-1184.
10. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced FN by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005;23: 7974-7984.
11. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439; erratum in J Clin Oncol 2003; 21:2226.
12. Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Huntingt) 2003;17(suppl 11):8-13.
13. Crawford J, Wolff D, Dale DC, et al. Assessment of neutropenic risk in cancer patients receiving systemic chemotherapy: results from a prospective nationwide registry [abstract]. Support Care Cancer 2004;12:374. Abstract A-29.
14. Crawford, J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
15. Komrokji RS, Lyman GH. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther 2004;4:1897-1910.
16. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21: 4524-4531.
17. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-Intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22: 4302-4311.
18. Dale D, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440-454.
19. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-237.
20. Lyman GH, Kuderer NM, Crawford J, et al. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy [abstract]. J Clin Oncol 2006;24 (Suppl 1):483s. Abstract 8561.
21. Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003;30(suppl 13):24-30.
22. Lokich JJ. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin's lymphoma. Am J Clin Oncol 2006;29:361-363.
23. Kaufman PA, Paroly W, Rinaldi D, et al. Randomized double blind phase 2 study evaluating same day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer [abstract]. Breast Cancer Res Treat 2004;88(suppl 1):S59. Abstract 1054.
24. Belani CP, Ramalingam S, Al-Janadi A, et al. A randomized double blind phase II study to evaluate same-day vs. next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC. J Clin Oncol 2006:24(Suppl 1):391s. Abstract 7110.
25. Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005;62:83-87.